Valuation: Diamyd Medical AB

Market Cap 159M 15.79M 14.03M 13.12M 11.95M 22.51M 1.52B 22.82M 61.44M 774M 59.3M 58.01M 2.49B P/E 2024
-10.2x
P/E 2025 -7.49x
Enterprise Value -118M -11.79M -10.47M -9.79M -8.92M -16.8M -1.14B -17.03M -45.87M -578M -44.27M -43.31M -1.86B EV / Sales 2024
11,578x
EV / Sales 2025 9,820x
Free-Float
83.81%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Diamyd Medical AB

1 day-0.78%
1 week-11.13%
Current month-0.78%
1 month+0.20%
3 months+0.20%
6 months-29.13%
Current year-90.92%
1 week 0.99
Extreme 0.992
1.11
1 month 0.97
Extreme 0.968
1.4
Current year 0.9
Extreme 0.896
17.88
1 year 0.9
Extreme 0.896
17.88
3 years 0.9
Extreme 0.896
25
5 years 0.9
Extreme 0.896
25.94
10 years 0.9
Extreme 0.896
74.7
Manager TitleAgeSince
Chief Executive Officer 85 24/04/2026
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 46 01/01/2013
Director TitleAgeSince
Chairman 85 02/10/2023
Director/Board Member 56 01/01/2009
Chairman 65 24/04/2026
Date Insider Type Main position Quantity % Market Cap. Importance
6/27/25 A Don

Chief Executive Officer

100,000 0.0791%
5/5/25 A Buy

Chief Executive Officer

1,000 0.0008%
5/2/25 A Buy 1,020 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-11.13%-91.29%-87.19% 15.76M
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.61%+0.81%+27.25%+82.72% 59.26B
-2.54%-1.65%+4.86%+31.72% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-3.57%+1.98%+28.45%+21.60% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.96%-1.59%+38.64%+130.01% 39.25B
Weighted average by Cap. -0.41%-0.32%+58.41%+146.01%

Financials

2024 2025
Net sales 130K 12.94K 11.49K 10.75K 9.79K 18.44K 1.25M 18.69K 50.32K 634K 48.57K 47.52K 2.04M 130K 12.94K 11.49K 10.75K 9.79K 18.44K 1.25M 18.69K 50.32K 634K 48.57K 47.52K 2.04M
Net income -152M -15.11M -13.42M -12.55M -11.44M -21.53M -1.45B -21.83M -58.78M -741M -56.74M -55.51M -2.38B -170M -16.9M -15.01M -14.03M -12.79M -24.08M -1.63B -24.41M -65.72M -828M -63.44M -62.06M -2.66B
Net Debt -132M -13.17M -11.7M -10.94M -9.97M -18.77M -1.27B -19.03M -51.24M -646M -49.46M -48.38M -2.07B -277M -27.58M -24.5M -22.91M -20.88M -39.31M -2.66B -39.85M -107M -1.35B -104M -101M -4.34B
Logo Diamyd Medical AB
Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.
Employees
44
Date Price Change Volume
01/10/26 SEK 1.022 -0.78% 436,731
30/09/26 SEK 1.030 +0.98% 236,025
29/09/26 SEK 1.020 +1.19% 1,021,231
28/09/26 SEK 1.008 -3.26% 1,089,661
25/09/26 SEK 1.042 -9.39% 2,827,784

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMYD B Stock